Patent applications published 17 November 2010
Selected patent applications from the weekly European Patents Bulletin
- Methods for the anti-inflammatory and anti-edematous protection of explanted biological material until the transplantation thereof in patients
Boehringer Ingelheim International 2249639*
- Novel compsns containing xanthohumol-cyclodextrin complexes
Flaxan 2249641*
- Pharmaceutical compsns of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
Merck Sharp & Dohme 2249643*
- Picoplatin and amrubicin to treat lung cancer
Poniard Pharmaceuticals 2249644*
- DNA vaccines and methods for the prevention of transplantation rejection
Loma Linda University 2249645*
- Dual pharmacophores - PDE4-muscarinic antagonists
Glaxo Group 2249646*
- Dual pharmacophores - PDE4-muscarinic antagonists
Glaxo Group 2249647*
- A method for modulating the release rate of microencapsulated actives
Endura 2249648*
- An improved process for preparation of paliperidone
Watson Pharma Private 2249649*
- Anilinopyridines as inhibitors of FAK
GlaxoSmithKline 2249650*
- Licorice lollipop that inhibits dental caries formation
Intelliherb 2249651*
- Magnetic cells for localising delivery and tissue repair
University of Miami 2249800*
- Stabilised protein compsns
Amgen 2249801*
- Compsn and method for assisting swallowing
University of East Anglia 2249802*
- Estradiol-containing drug delivery
Bayer Schering Pharma 2249803*
- Implantable product containing nanoparticles
MagForce Nanotechnologies 2249804*
- Liquid antiseptic compsns containing iodine and a sugar and/or sugar alcohol
3M Innovative Properties 2249805*
- Resveratrol formulations
Sirtis Pharmaceuticals 2249806*
- Suspension formulations
Vectura; Innovata Biomed 2249807*
- Solid pharmaceutical dosage form
Cipla 2249808*
- Powdered protein compsns and methods of making same
Abbott 2249809*
- Method fro lyophilising particles having a pharmaceutical compound contained therein and a pharmaceutical pack containing such particles
Intervet International 2249810*
- Pharmaceutical dosage form
Grünenthal 2249811*
- Oral pharmaceutical formulations containing gliclazide
Valpharma 2249811*
- Use of magnesium stearate dihydrate for lubrication of solid pharma compsns
Mallinckrodt 2249813*
- Combination of oral medicaments bonded by a wrapping
Duo-Ge 2249815*
- Formulation and method for the prevention and treatment of bone metastases or other bone diseases
Erytech Pharma 2249816*
- Nanoparticle carriers for drug administration and process for producing same
CSIR 2249817*
- Hedgehog pathway antagonists and methods of use
Stanford University 2249818*
- Phytol as a cholesterol lowering agent
Olofsson, Peter; Hultqvist, Malin; Holmdahl, Rikard 2249819*
- TRPA1 antagonists
Abbott Laboratories 2249820*
- Use of amidoxime carboxylic acid esters and N-hydroxyguanidine carboxylic acid esters for producing prodrugs
Dritte Patentportfolio Beteilgungsgesellschaft 2249821*
- Pharmaceutical compsns and methods utilising a D-amino acid and an antioxidant for treating neuropsychiatric disorders
Amino Acid Solutions 2249822*
- Octanoic acid formulations and methods of treatment using the same
The Govt of the USA as represented by the Secretary of the Department of Health and Human Services 2249823*
- Lactylates for the prevention and treatment of infections caused by Gram-positive bacteria in animals
PURAC Biochem 2249824*
- Treatment methods and compsns for lung cancer, adenocarcinoma, and other medical conditions
Bionumerik Pharmaceuticals 2249825*
- Compsns and methods of use of compounds to increase cancer patient survival time
Bionumerik Pharmaceuticals 2249826*
- Use of picoplatin and cetuximab to treat colorectal cancer
Poniard Pharmaceuticals 2249827*
- Preparation of sulphamide derivatives
Janssen Pharmaceutica 2249828*
- Tetrahydropyridoethers for treatment of AMD
Schraermeyer, Ulrich 2249829*
- Dual pharmacophores - PDE4-mascarinic antagonistics
Glaxo Group 2249830*
- Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino))-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridin-3-carboxylic acid for the treatment of antecedant haematologic disorders
Sunesis Pharmaceuticals 2249831*
- Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
Agency for Science, Technology and Research, Singapore 2249832*
- Prodrugs of CGRP receptor antagonist
Merck Sharp & Dohme 2249833*